Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit: real-world data from the German SAL-AML registry.

J Cancer Res Clin Oncol · 2023 · PMC10349710 · PMID 36167894

Europe PMC DOI

hedged sentence

0.1600

closest p · 3.2× alpha

0.1600

boldest claim

The sentences

did not reach statistical significancep = 0.16not close (p > 0.1)

A trend for superior RFS for HiDAC-treated patients appeared with a 2-year survival rate of 62.7% compared to 47.0% for patients consolidated with IDAC, which, however, did not reach statistical significance (HR = 1.453, p = 0.16) (Fig. 3 B).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.